PSNL News and Press, Personalis Inc. From 03/29/20

Personalis ( PSNL ) has triggered my interest since it has gone public in the summer of 2019. With PSNL reporting its full-year results in the middle of the Corona crisis, it is time to update my stance on the company. Fourth-quarter results were more or less in line with expectations, and d...

Image source: The Motley Fool. Personalis, Inc.   (NASDAQ: PSNL) Q4 2019 Earnings Call Mar 25, 2020 , 5:00 p.m. ET Operator Continue reading

Personalis, Inc. (PSNL) Q4 2019 Earnings Conference Call March 25, 2020 5:00 p.m. ET Company Participants Caroline Corner - Westwicke ICR John West - President and CEO Aaron Tachibana - CFO Clinton Musil - Chief Business Officer Conference Call Participants Derik De Bruin...

Personalis (NASDAQ: PSNL ): Q4 GAAP EPS of -$0.21 beats by $0.06 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Full Year 2019 Highlights Reported record revenues of $18.2 million in the fourth quarter an...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its fourth quarter and full year 2019 financial results after the market closes on Wednesday, March 25, 2020. In conjunction with the release, the Company will host a conference call and...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Immuno-Oncology 360˚ conference in New York, February 26-28. The presentation , titled “Comprehensive Immunogenomics to Enable Composite Biomarkers fo...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the Biomarkers Series UK 2020 conference in Manchester, UK, February 19-20. The presentation , titled “Maximizing Immunotherapy Biomarker Discovery with an A...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40 th Annual Health Care Conference. John West, Chief Executive Officer, will be presenting on Wednesday, March 4, 2020 at 8:40 a.m. E...

Advaxis (NASDAQ: ADXS ) and Personalis (NASDAQ: PSNL ) have collaborated to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lu...